. TEM images of as-synthesized DCNPs (a) TEM images of NaGdF 4 :5%Nd@NaGdF 4 DCNPs. (b) TEM images of water-soluble NaGdF 4 :5%Nd@NaGdF 4 DCNPs. Scale bar = 20 nm. The University of Queensland, Australia. All chemicals were used as received without any further purification.
Synthesis of NaGdF 4 :5%Nd core DCNPs
The synthesis of the NaGdF 4 :Nd core DCNPs with a size of ~ 14 nm in this work was similar to the synthesis previously reported by Prasad et al. 1 In a typical procedure, 0.95 mmol GdCl 3 , 0.05 mmol NdCl 3 , 6.0 mL OA and 15.0 mL ODE were mixed together and heated to 120 C under vacuum until a clear solution formed. After that, the solution was cooled to room temperature. A solution of 2.5 mmol NaOH and 4.0 mmol NH 4 F in 10 mL methanol was added and the mixture was stirred for one hour. The reaction mixture was then heated at 80 C to remove the methanol.
Afterward, the solution was heated to 290 C and maintained at that temperature for 60 min under a gentle argon flow. Subsequently, the solution was cool down to room temperature and the DCNPs were precipitated, centrifuged and washed twice with ethanol. The DCNPs were finally dispersed in 10 mL of cyclohexane for further use.
Synthesis of NaGdF 4 :5%Nd@NaGdF 4 core/shell DCNPs
Gd-OA (0.10 M) precursor: a mixture of 2.50 mmol GdCl 3 , 10.0 mL OA, and 15.0 mL ODE were loaded in a reaction container and heated at 140 °C under a vacuum with magnetic stirring for 30 min to remove residual water and oxygen. Then the colorless Gd-OA precursor solution (0.10 M) was obtained.
Na-TFA-OA precursor: A mixture of 4.0 mmol Na-TFA and 10 mL OA was loaded in a container at room temperature under vacuum with magnetic stirring to remove residual water and oxygen.
Then the colorless Na-TFA-OA precursor solution (0.40 M) was obtained. 
Transferring NaGdF 4 :5%Nd@NaGdF 4 DCNPs from hexane solution to aqueous
The phase transfer method used in this work was similar to the method previously reported by Yao et al. 2 Typically, 1 mL of oleic acid capped DCNPs in cyclohexane (10 mg mL -1 ) was mixed with a cyclohexane solution (1 mL) containing 12.5 mg DSPE-PEG-NH 2 in a glass bottle. The glass
bottle was left open in a fume hood for two days at room temperature to evaporate the cyclohexane slowly. The resulting mixed film was heated at 75 °C for 5 min to completely remove cyclohexane.
Then the film was hydrated with 5 mL water, and the DCNPs became soluble after vigorous sonication and further stirred vigorously at 75 °C for 10 min. The solution was transferred to a microtube and centrifuged and the sediment was discarded to remove possible formation of large aggregates. Excess lipids were purified by ultracentrifugation (15000 rpm, 10 min) and washing.
Preparation of SiO 2 particles
6 mL NH 3 ·H 2 O (28 wt. %). After continuous stirring at room temperature for two hours, the products were precipitated by adding ethanol. The collected precipitates were washed twice with water and dispersed in 10 mL water for further use.
Preparation of SiO 2 -Nd
DCNPs were assembled on the surface of SiO 2 particles by simply mixing them in water.
Typically, 2.5 mL of as-synthesized lipid modified DCNPs were added to 2 mL aqueous dispersion of SiO 2 particles. Then, the mixture was gently stirred for 6 hours at 50 °C , followed by washing with water to remove free DCNPs. It is noted that free DCNPs dispersed in the solution can be concentrated and reused again.
Preparation of SiO 2 -Nd@SiO 2
In a typical synthesis, the SiO 2 -Nd were re-dispersed in a mixed solution containing 6 mL H 2 O, 14 mL ethanol and 0.2 mL NH 3 ·H 2 O with ultrasonication treatment. Subsequently, 0.2 mL of TEOS was added dropwise into the solution. After reaction for 8 h at room temperature, the product was collected by centrifugation and washed with ethanol and water.
Preparation of SiO 2 -Nd@SiO 2 @mSiO 2
The mesoporous silica shell with large pore size were coated on the surface of SiO 2 -Nd@SiO 2 through an oil-water biphase stratification approach by using CTAC as the surfactant template in an alkaline system. 4 In brief, SiO 2 -Nd@SiO 2 in was added into a solution containing 48 mL of H 2 O, 12 mL of 25 wt. % CTAC/H 2 O and 0.18 mL of TEA, followed by the ultrasonication (0.5 h) and stirring(60 °C for 1 h) treatment. Afterwards, 10 mL of TEOS (10 v/v % in cyclohexane) was gently dropped into the upper solution and capped with a stopper. The system was reacted at 60 °C for 12 h in an oil bath with gentle mechanical stirring (200 rpm). The products were collected by centrifugation, and then washed with ethanol and water for several cycles. The template CTAC surfactants and hydrophobic organic phase in the mesopore channels were removed through a solvent extraction method by using 2 wt. % of HCl/ethanol solution refluxed at 60 °C for 10 h. This extraction process was repeated twice to obtain the SiO 2 -Nd@SiO 2 @mSiO 2 .
Preparation of SiO 2 -Nd@SiO 2 @mSiO 2 -NH 2
The amino-modification was achieved via a post-grafting strategy. In a typical process, 15 mL of anhydrous toluene and 100 mg of extracted SiO 2 -Nd@SiO 2 @mSiO 2 were mixed in a 25 mL round-bottomed flask and stirred vigorously. After formation of a homogeneous suspension, 0.1 mL of APTES was added dropwise to the toluene solution. The reaction was kept at 110 °C with reflux for 20 h. The amino-functionalized products were collected by centrifugation and washed for several times with ethanol to remove the residual reactants and subsequently lyophilized to obtain the dry powder for the next experiments.
Preparation of SiO 2 -Nd@SiO 2 @mSiO 2 -NH 2 @SSPI
SSPI can be obtained by succinylating SPI using a modified literature method. with MES buffer to remove unreacted SSPI followed by lyophilizing.
Similar procedures were done on the PEP-NPTAT loaded SiO 2 -Nd@SiO 2 @mSiO 2 -NH 2 @SSPI.
Preparation of 25, 80 and 300 nm microcarriers
Both 25 and 80 nm microcarriers were synthesized by a reversed-phase microemulsion method.
In a typical procedure to synthesize 25 nm microcarrier, 30 mg NaGdF 4 :5%Nd core DCNPs (~ 10 nm) were added to a mixing solution of 2.5 mL CO-520, 20 mL cyclohexane and 0.3 mL NH 3 ·H 2 O (28 wt. %), and the container was sealed and sonicated for 15 min until a transparent reversed-phase microemulsion was formed. Then, 0.1 mL TEOS was added into the solution. After continuous stirring at room temperature at the speed of 450 rpm for two days, products were precipitated by adding ethanol. The collected precipitate was washed with ethanol twice and dispersed in saline water. To synthesize 80 nm microcarrier, the procedure was similar that of the 25 nm microcarrier, except that NaGdF 4 :5%Nd@NaGdF 4 core/shell DCNPs (~ 40 nm) were used, instead of NaGdF 4 :
5%Nd core DCNPs.
300 nm microcarrier were synthesized by coating mesoporous silica shell on the 80 nm microcarrier. The procedure was similar with the preparation of SiO 2 -Nd@SiO 2 @mSiO 2 , except that 80 nm microcarrier were used as seeds, instead of SiO 2 -Nd@SiO 2 .
All of these particles were modified with amino group, followed by SSPI grafting. The synthesis procedure was similar to the preparation of SiO 2 -Nd@SiO 2 @mSiO 2 -NH 2 @SSPI.
Preparation of simulated body fluids
Simulated gastric fluid: 2.0 g NaCl was dissolved to 1000 mL H 2 O, then the pH was adjusted to 1.0 using 1 M HCl. 
Power dependence study of the NIR-II emission intensities of DCNPs
By increasing the pump power density up to 4.55 W cm -2 , both 730-nm excited and 808-nm excited NIR-II emission intensities increased proportional to the increase of power density ( Supplementary Fig. 11a,b) . Significantly, when the power density was below this threshold (4.55 W cm -2 ), the NIR-II emission intensity under 730-nm was about 62% of that obtained under 808-nm excitation (F 730 /F 808 ) ( Supplementary Fig. 11c ). Beyond this threshold, the NIR-II emission intensity under 730-nm excitation quickly reached a plateau while NIR-II emission intensity under 808-nm excitation maintained increasing, leading to decrease of F 730 /F 808 ( Supplementary Fig. 11c,d ). Since safe-exposure limit of laser for small animals (0.23 W cm -2 at 730 nm and 0.33 W cm -2 at 808 nm) 6 , the laser power density used in the present work was much lower than 4.55 W cm -2 , which means that the F 730 /F 830 would be a constant (~ 0.62) in the experiment.
In vivo pharmacokinetics investigation of BSA by using radioisotopic tracing method 7 1000 nm microcarriers were used in the following experiment.
Labeling and Purification of 125 I-BSA
BSA was radiolabeled with 125 I-Na using iodogen method. Labeled BSA was separated using The elution fractions were collected and free 125 I in the fraction was removed using ultrafiltration tubes with a molecular weight cutoff of 1 kDa. The purity of 125 I-BSA was assessed using HPLC method and SDS-PAGE. The radioactivity was measured using γ-counter. The resulting radiochemical purity and activity concentration of the resulting 125 I-BSA was measured to be 98% and 1.54 μCi μg -1 .
Fabrication of 125 I-BSA loaded microcarriers
0.7 mg 125 I-BSA was mixed with 4.3 mg un-labeled BSA in 2 mL MES buffer (0.1 M, pH 5), followed by 15 min stirring at room temperature. 12 mg SiO 2 -Nd@SiO 2 @mSiO 2 -NH 2 was soaked into this solution, followed by stirring at room temperature for 1 h. The as-prepared 125 I-BSA-NPTAT loaded SiO 2 -Nd@SiO 2 @mSiO 2 -NH 2 was collected by centrifugation (3000 rpm) and redispersed in 2 mL MES buffer. Then, 3 mL of above SSPI solution (4 mg mL -1 in 0.1 M MES buffer) was added quickly, and the obtained turbid solution was further stirred for 1 hours at room temperature. The resulting microcarriers were finally centrifuged at 3000 rpm and washed several times with MES buffer to remove unreacted SSPI. By measuring the radiation dose of the supernatants, loading efficiency was calculated to be 18.2%.
In vivo pharmacokinetics investigation
Kunming mice (5-6 weeks, female) were fasted for 12 h before experiment. Then the animals were randomized into four groups with n = 3 per group. Mice in all groups received a single dosage of 125 I-BSA loaded microcarriers (50 mg kg -1 ) via oral gavaging. The animals were sacrificed at 2, 6, 12 or 72 h after gavaging. Blood, excretion (including urine and feces) and tissues (including stomach, intestine, liver and kidney) were collected and weighed. Before measuring radioactivity,
Investigation of in vivo drug release kinetics
For the first 12 hours of drug release in vivo, which corresponds to about 50% of released drug, the release rates differ greatly with those after 12 h, therefore, the release data before 12 h and after 12 h were fitted separately. Taking BSA-NPTAT loaded microcarriers as an example, the release percentage data were fitted to the following equation:
Where Q (τ) is the release percentage of the BSA-NPTAT at time τ (Fig. 6c) , k is release rate constant, and n is the release exponent, indicative of the mechanism of release.
Supplementary Fig. 13 showed that release percentage data before 12 h and after 12 h both behave as one-order release system (release exponent n = 1), except the release rate constant k before 12 h (7.212 (% h -1 )) is much larger than the latter (0.222 (% h -1 )).
Characterization
Transmission electron microscopy (TEM), high-resolution transmission electron microscopy (HRTEM), selected area electron diffraction (SAED) and electron energy loss spectroscopy (EELS)
observations were performed with a JEM-2100F transmission electron microscope with an accelerating voltage of 200 kV equipped with a post-column Gatan imaging filter (GIF-Tri-dium).
Visible FL spectra were recorded on Edinburgh Fluorescence Spectrometer FLS980 instrument with Xenon lamp as excitation source. While NIR FL spectra were also recorded on this instrument, but excitation source were using external 808-nm or 730-nm semiconductor laser (Changchun New Industries Optoelectronics Tech. Co., Ltd.), instead of the Xenon source in the spectrophotometer (Unless otherwise specified, all spectra were collected under identical experimental conditions). The UV/Vis spectra were recorded on Lambda 35 PerkinElmer. Optical luminescence imaging of the mice organs after dissection was performed with LB983 NightOWL II (Berthold Technologies
GmbH & Co.KG, Germany). In vivo NIR images was taken using NIR vana CCD camera (Princeton Instruments Inc.). The distribution of microcarriers were determined by measuring silicon content in different organs by inductively coupled plasma atomic emission spectrometry (ICP) using an IRIS Advantage Duo ER/S (Thermo Fisher Scientific).
